USE OF BETA-BLOCKERS AND REDUCTION IN ALL-CAUSE MORTALITY IN HOSPITALIZED MEDICARE BENEFICIARIES WITH ACUTE DIASTOLIC HEART FAILURE: A PROPENSITY-MATCHED STUDY OF THE OPTIMIZE-HF
| Autor: | Meredith L. Kilgore, Marjan Mujib, Gregg C. Fonarow, Margaret A. Feller, Ali Ahmed, Yan Zhang, Tarun Arora, Richard M. Allman, Inmaculada Aban, Thomas E. Love |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Pediatrics Ejection fraction Proportional hazards model business.industry Diastole medicine.disease Lower risk Internal medicine Heart failure Acute diastolic heart failure Cohort Propensity score matching medicine Cardiology business Cardiology and Cardiovascular Medicine |
| Zdroj: | Journal of the American College of Cardiology. 57(14) |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(11)60222-2 |
| Popis: | Category: 21. Myocardial Function/Heart Failure—Clinical Pharmacological TreatmentSession-Poster Board Number: 1017-43Authors: Ali Ahmed, Yan Zhang, Marjan Mujib, Tarun Arora, Margaret Feller, Meredith Kilgore, Inmaculada Aban, Thomas Love, Richard Allman, Gregg Fonarow, UAB, Birmingham, AL, VAMC, Birmingham, ALBackground: Beta-blockers (BB) reduce mortality in systolic heart failure (HF). However, evidence of their beneits is unclear in diastolic HF. We tested the hypothesis that BB use would lower mortality in diastolic HF enrolled into the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry.Methods: Of the 9165 unique OPTIMIZE-HF patients hospitalized with acute diastolic HF (LVEF ≥45%) linked with Medicare outcomes data, 5434 (59%) were prescribed BBs at discharge. Propensity scores for BB use were estimated for each of the 9165 patients and were used to assemble a cohort of 3382 pairs of patients receiving and not receiving BBs who were balanced on 38 baseline characteristics.Results: Patients (n=6764) had a mean (SD) age of 78 (11) years, 65% were women, 12% were African American, and a mean (SD) LVEF of 0.58 (0.09) %. During ~6 years of follow-up, all-cause mortality occurred in 69% and 72% of matched patients receiving and not receiving BBs respectively (HR when BB use was compared with its non-use, 0.90; 95% CI, 0.85-0.96; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|